EA201590297A1 - Гетероциклические карбоксамиды для лечения вирусных заболеваний - Google Patents

Гетероциклические карбоксамиды для лечения вирусных заболеваний

Info

Publication number
EA201590297A1
EA201590297A1 EA201590297A EA201590297A EA201590297A1 EA 201590297 A1 EA201590297 A1 EA 201590297A1 EA 201590297 A EA201590297 A EA 201590297A EA 201590297 A EA201590297 A EA 201590297A EA 201590297 A1 EA201590297 A1 EA 201590297A1
Authority
EA
Eurasian Patent Office
Prior art keywords
viral diseases
treatment
heterocyclic carboxamides
methods
unit doses
Prior art date
Application number
EA201590297A
Other languages
English (en)
Other versions
EA027810B1 (ru
Inventor
Элиэзер Хуберман
Original Assignee
НОВАДРАГ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by НОВАДРАГ, ЭлЭлСи filed Critical НОВАДРАГ, ЭлЭлСи
Publication of EA201590297A1 publication Critical patent/EA201590297A1/ru
Publication of EA027810B1 publication Critical patent/EA027810B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Описаны способы, варианты использования, лекарственные средства и стандартные дозы для лечения вирусных заболеваний. Указанные способы, варианты использования, лекарственные средства и стандартные дозы включают замещенные пиперидинкарбоксамиды и пиперазинкарбоксамиды. Вирусные заболевания включают вирус гепатита С, ВИЧ, вирус бычьей вирусной диареи и коронавирусные инфекции.
EA201590297A 2012-08-31 2013-08-30 Гетероциклические карбоксамиды для лечения вирусных заболеваний EA027810B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695869P 2012-08-31 2012-08-31
US201361779595P 2013-03-13 2013-03-13
PCT/US2013/057585 WO2014036443A2 (en) 2012-08-31 2013-08-30 Heterocyclyl carboxamides for treating viral diseases

Publications (2)

Publication Number Publication Date
EA201590297A1 true EA201590297A1 (ru) 2015-08-31
EA027810B1 EA027810B1 (ru) 2017-09-29

Family

ID=50184664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590297A EA027810B1 (ru) 2012-08-31 2013-08-30 Гетероциклические карбоксамиды для лечения вирусных заболеваний

Country Status (14)

Country Link
US (1) US9511070B2 (ru)
EP (1) EP2922596B1 (ru)
JP (1) JP5976224B2 (ru)
KR (1) KR20150048132A (ru)
CN (1) CN104582794A (ru)
AU (1) AU2013308535B2 (ru)
CA (1) CA2881901C (ru)
EA (1) EA027810B1 (ru)
ES (1) ES2684396T3 (ru)
HK (1) HK1209674A1 (ru)
IL (1) IL237119A (ru)
IN (1) IN2015KN00302A (ru)
WO (1) WO2014036443A2 (ru)
ZA (1) ZA201501430B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2892534B8 (en) * 2012-09-06 2021-09-15 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
US9896450B2 (en) * 2015-05-04 2018-02-20 Ohio State Innovation Foundation Modulators of Clavibacter michiganensis and methods of making and using thereof
WO2020028482A1 (en) * 2018-07-31 2020-02-06 The Trustees Of The University Of Pennsylvania Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity
WO2022053993A2 (en) * 2020-09-12 2022-03-17 Mylan Laboratories Limited Treatments for sars-cov-2 infection (covid-19)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2792399A (en) * 1954-05-29 1957-05-14 Bofors Ab Anilides of heterocyclic compounds
AU3289299A (en) * 1998-02-19 1999-09-06 Tularik Inc. Antiviral agents
AU2002221923A1 (en) * 2000-11-28 2002-06-11 Glaxosmithkline S.P.A. Novel compounds
KR100900304B1 (ko) 2001-06-11 2009-06-02 바이로켐 파마 인코포레이티드 플라비 바이러스 감염용 항바이러스제로서의 티오펜 유도체
AU2002359327A1 (en) * 2001-10-30 2003-05-12 Thomas Jefferson University Method of treating viral infections
AU2003260198A1 (en) * 2002-08-30 2004-03-19 Chiron Corporation Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents
KR100502394B1 (ko) * 2003-06-04 2005-07-19 (주) 비엔씨바이오팜 2-[2-(4-모르포리노)에틸아미노]피리딘 유도체, 그제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
US8188277B2 (en) 2004-08-06 2012-05-29 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds for suppressing the generation of collagen
GB0421908D0 (en) * 2004-10-01 2004-11-03 Angeletti P Ist Richerche Bio New uses
CA2596393C (en) * 2004-12-30 2014-09-23 Janssen Pharmaceutica N.V. 4-(benzyl)-piperazine-1-carboxylic acid phenylamide derivatives and related compounds as modulators of fatty acid amide hydrolase for the treatment of anxiety, pain and other conditions
CA2612788A1 (en) * 2005-06-24 2006-12-28 Steven Cesar Alfons De Jonghe Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis c
WO2009010480A1 (en) * 2007-07-13 2009-01-22 Euroscreen S.A. 1-{2-[(diphenyl)amino]-ethyl}-piperidine-4-carboxylic acid benzylamide derivatives and related compounds as ccr5 agonists for the treatment of immune and inflammatory diseases
WO2010101246A1 (ja) * 2009-03-05 2010-09-10 塩野義製薬株式会社 Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体
KR101168801B1 (ko) * 2009-03-27 2012-07-25 주식회사종근당 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물
US20120208204A1 (en) * 2009-06-03 2012-08-16 The Brigham And Women's Hospital, Inc. Compositions and Methods for Inhibiting Tumor Growth
US20120225097A1 (en) * 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
WO2011060396A1 (en) * 2009-11-16 2011-05-19 Schering Corporation Aliphatic amines based heterocycles useful as hiv entry blockers
EP2515908A2 (en) * 2009-12-22 2012-10-31 Merck Sharp & Dohme Corp. 1,4-substituted piperazine derivatives and methods of use thereof
WO2011091152A1 (en) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibitors of hepatitis c virus infection
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2013116491A1 (en) 2012-02-01 2013-08-08 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds and methods for using them

Also Published As

Publication number Publication date
AU2013308535A1 (en) 2015-02-26
ZA201501430B (en) 2016-01-27
CA2881901A1 (en) 2014-03-06
EP2922596A2 (en) 2015-09-30
IN2015KN00302A (ru) 2015-06-12
AU2013308535B2 (en) 2016-10-20
EP2922596B1 (en) 2018-05-23
US20150238489A1 (en) 2015-08-27
CA2881901C (en) 2017-10-10
JP2015532652A (ja) 2015-11-12
EA027810B1 (ru) 2017-09-29
KR20150048132A (ko) 2015-05-06
CN104582794A (zh) 2015-04-29
WO2014036443A2 (en) 2014-03-06
HK1209674A1 (en) 2016-04-08
ES2684396T3 (es) 2018-10-02
WO2014036443A3 (en) 2014-04-24
IL237119A (en) 2017-08-31
US9511070B2 (en) 2016-12-06
JP5976224B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
PH12018500572A1 (en) Hepatitis b core protein modulators
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
BR112017012859A2 (pt) fosforamidatos para o tratamento do vírus da hepatite b
EA201490588A1 (ru) Способы лечения вируса гепатита с
GT201500020A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
EA201500207A1 (ru) Гетероароматические соединения в качестве ингибиторов втк
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
PH12015502230B1 (en) Novel viral replication inhibitors
MX354676B (es) Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv).
EA201590297A1 (ru) Гетероциклические карбоксамиды для лечения вирусных заболеваний
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
EA201691835A1 (ru) Аллостерические модуляторы капсидного белка гепатита в
BR112016020895A2 (pt) moduladores alostéricos da proteína do núcleo da hepatite b
EA201791356A1 (ru) Фосфорамидаты для лечения вируса гепатита в

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU